Acquisition will create phage therapy company with an advanced pipeline with two Phase 2 assets, BX004 for the treatment of chronic pulmonary infections in cystic fibrosis (“CF”) patients and BX211 for the treatment of diabetic foot osteomyelitis (“DFO”)
Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive agreement for a private placement financing of $50 million that will be used to advance two lead product candidates through Phase 2 clinical readouts in 2025
Conference call today at 9:00 a.m. EST
Participant Dial-In Number: | 877-407-0724 |
Participant International Dial-In | +1 201-389-0898 |
Webcast: |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.